

## RESULTS OF SHARE PURCHASE PLAN OFFER

---

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or 'the Company'), an agtech development company enabling the next generation of novel insecticides to address insecticide resistance, is pleased to announce that it has received \$428,000 in applications for 2,761,276 fully paid ordinary shares at the issue price of 15.5 cents under the 2020 Share Purchase Plan ("SPP") which closed on 16 June 2020.

The SPP is part of a capital initiative to raise up to \$3.9 million, as announced on 26 May 2020, to strengthen the Company's Balance Sheet and fund its operations including to:

- Continue and expand commercialisation discussions;
- Accelerate registration enabling studies;
- Enable additional research on product efficacy and Mode of Action; and
- General working capital.

Combined with the proceeds from the Placement of \$2.4 million, Bio-Gene has raised a total of \$2.8 million from this initiative to date.

The Company will now seek to place the shortfall of up to approximately 6,916,129 SPP shares to professional, sophisticated and other exempt investors. Further announcements will be made regarding any shortfall placement at the applicable times.

An Appendix 2A will be released to ASX when the SPP shares are issued on 22 June 2020. Holding statements will be dispatched to successful applicants and trading of the SPP shares on ASX is expected to commence on 23 June 2020. Shares issued under the SPP will rank equally with Bio-Gene's existing ordinary shares upon issue.

Approved for release by the Chairman of the Board.

- ENDS -

### For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger  
Chief Executive Officer  
P: 03 9068 1062  
E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Roger McPherson  
CFO & Company Secretary  
P: 03 9068 1062  
E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Media/Investor Relations:

Davina Gunn  
Henslow  
T: 0400 896 809  
E: [dgunn@henslow.com](mailto:dgunn@henslow.com)

### About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across Crop Protection, Grain Storage, Public Health and Consumer Products. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and pest management solutions.